Table 2– Main studies assessing exhaled nitric oxide fraction and nasal nitric oxide in patients with primary ciliary dyskinesia (PCD) compared to healthy controls
PCDHealthy controlsp-valueRef.
FeNO50 ppb2.1 (1.3–3.5) (n=14)6.7 (2.6–11.9) (n=37)0.001[47]
2.9 (1.9–4.6)# (n=17)6.4 (4.8–8.6)# (n=24)0.11+[48]
8.1 (1.3)# (n=24)12.5 (1.6)# (n=20)0.033[49]
3.2 (0.2)# (n=15)8.5 (0.9)# (n=14)<0.0001[50]
7.1 (5.7–8.8)# (n=20)13.9 (11.7–16.4)# (n=20)<0.01[51]
Nasal NO ppb54.5 (5.0–269) (n=14)663 (322–1343) (n=37)<0.001[47]
64±36.6 (n=42)759±145.8 (n=16)<0.0001[52]
13.7 (6.8–27.8)# (n=17)223.7 (175.5–285.2)# (n=24)<0.05[48]
59.6±12.2 (n=15)505.5±66.8 (n=14)<0.001[50]
49 (34–64)# (n=20)639 (422–890)# (n=20)<0.01[53]
142±42 (n=45)908±33 (n=49)<0.0001[53]
55 (3.3–959) (n=21)553 (116±1437) (n=20)<0.001[7]
4 (1)# (n=4)221 (14)# (n=20)<0.001[3]
  • Data are presented as median (range) or mean±sd, unless otherwise stated. FeNO50: exhaled nitric oxide measured at a set exhalation flow rate of 50 mL·s−1. #: mean (95% CI); : mean±se; +: nonsignificant.